Boston Scientific buys nVision Medical

NEC Member Boston Scientific recently announced its purchase of nVision medical, a California med-tech firm that’s developing a device to screen women for ovarian cancer. It was reported that Boston Scientific will pay $150 million upfront and another $125 million in later payments, totaling a $275 million purchase.

Boston Scientific sees large market potential of around $500 million per year for nVision’s devices, predicting that the market eventually could grow to $2 billion. The reason the device is valuable is that there has not previously been a  screening test for this particular form of cancer and that current testing methods yield false-positives leading to unnecessary surgery.

The deal marks Boston Scientific’s second cancer-related acquisition in recent weeks, having previously bought Minnesota’s NxThera which makes devices to treat enlarged prostates.

The New England Council congratulates Boston Scientific for its continued growth and looks forward to the continued development of this important cancer screening tool. Read more on Boston Business Journal.

img_side
mask_sidebar
Recently from the Blog

PwC Launches Digital Boot Camp for Employees

07/31/2018 | Read Post

Citizens Donates $1M to Feeding America & Announces Partnership

07/31/2018 | Read Post

In the News

NEC to Honor New Englanders of the Year at 2017 Annual Dinner

10/25/2017 | Read Press Release

NEC Elects Six Respected Regional Business Leaders to Board of Directors

09/25/2017 | Read Press Release